About Centogene
Centogene is a publicly listed company based in Rostock (Germany) founded in 2006. It operates as a provider of biochemicalgenetic tests to detect mutations and rare diseases. Centogene has raised $28.02 million across 3 funding rounds from investors including Deutsche Private Equity, Careventures and TVM Capital Life Science. The company has 11 employees. Its website centogene.com draws about 28 thousand monthly visits. Its Indian entity Centogene India Private Limited reported revenue of ₹3.64 Cr. Centogene offers products and services including CentoGenome, CentoXome, MOx, and NGS Panels. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include Invitae, Strand Life Sciences, Myriad Genetics, Genome Medical and Fulgent Genetics and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
Founded in 2006 in Rostock, Germany, operations focus on the genetic diagnostics sector. A database called CentoMD is maintained, containing disease-causing mutations with a phenotype-genotype search tool based on the Human Phenotype Ontology. Genetic panel tests and single mutation tests are offered, alongside analytical services for neonatal screening of congenital diseases, as well as detection of breast cancer, mitochondrial disorders, infertility, stroke, vascular dementia, somatic cancer mutations, and Fabrys disease.
- Headquarters Rostock, Germany
- Employees 11
- Stage Public
- SectorsHealthcare
- Website centogene.com
- Social LinkedIn X YouTube
- Legal Name Centogene N.V.
- Annual Revenue₹3.64 Cr
FY 2025 · +4% YoY
- Net Loss-₹45.4 Lakh
FY 2025 · -12% margin
- EBITDA-₹45.3 Lakh
FY 2025 · -12% margin
- Total Equity Funding$28.02M (USD)
in 3 rounds
- Latest Funding Round$16.78M (USD), Post-IPO
Feb 2022
- InvestorsDeutsche Private Equity
& 3 more
- Employee Count11
Associated legal entities of Centogene
Centogene operates through Centogene India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Centogene India Private Limited CIN U85100DL2012PTC239252 | Active | 24 Jul 2012 | Delhi, Delhi | ₹3.6 Cr | 11 | 3 | View details |
Products & Services of Centogene
Centogene offers a comprehensive portfolio of products and services, including CentoGenome, CentoXome, MOx, and NGS Panels.
Whole genome sequencing for comprehensive rare disease diagnostics
Whole exome sequencing for cost-effective patient diagnosis
Multiomics platform for deeper biological process understanding
Targeted panels for hereditary condition diagnostics
Apps and channels of Centogene
its YouTube channel CENTOGENE GmbH has 974 subscribers and 30 videos.
Videos from Centogene
The most watched videos on Centogene's YouTube channel, CENTOGENE GmbH (974 subscribers). Click a video to play it here.
More on CENTOGENE GmbH.
Funding Insights of Centogene
Centogene has successfully raised a total of $28.02M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $16.78 million completed in February 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $28.02M
- Total Rounds 3
- Last Round Post-IPO — $16.78M
- First Round $28.02M
(Jun 2017)
- Investors Count 4
All 3 funding rounds of Centogene with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2022 | $16.78M | Post-IPO | – | – | |
| Jul 2020 | $28M | Post-IPO | – | – | – |
| Jun 2017 | $28.02M | Series A | – | TVM Capital |
4 investors in total: 4 institutional.
Investors in Centogene
Centogene has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Deutsche Private Equity, Careventures and TVM Capital Life Science.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm | 2007 | dpe.de | Munich, Germany | |
Careventures is focused on healthcare investments across Europe. | – | careventures.eu | Brussels, Belgium | |
Capital is invested in life science innovations for healthcare transformation. | – | tvm-capital.com | Munich, Germany | |
Growth and acquisition investments are managed by Credit Mutuel Equity. | – | creditmutuel-equity.eu | Paris, France |
Investor details for Centogene
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Centogene India Private Limited (Centogene)
Centogene India Private Limited is the primary company behind Centogene. The board of Centogene India Private Limited currently have 3 directors; the longest-serving is Nabendu Das, appointed in 2020. 10 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Nabendu Das DIN 08741035 | Director | 01 Apr 2020 | 6 yrs 6 mo | Centogene India Private Limited |
| Francisco De Borja Valor Martinez DIN 07663818 | Director | 27 Jun 2025 | 1 yr 3 mo | Centogene India Private Limited |
| Dawood Babu Dudekula DIN 11407827 | Additional Director | 03 Dec 2025 | 10 mo | Centogene India Private Limited |
People of Centogene
56 people are tracked at Centogene (26 in leadership, 7 in board & advisors, 23 in team); the tracked headcount is 11.
| Name | Role | Group |
|---|---|---|
Ellen Karges | VP Of Pharmaceutical Compliance | Leadership |
Aakanksha Malik-Nair | Chief Growth & Execution Officer | Leadership |
Osterholz | Head Of HR | Leadership |
Peter Bauer | Chief Genomic Officer | Leadership |
Dr. Katja Brüsehafer | Vice President Multiomics Wetlab & Development | Leadership |
Claudia Cozma | VP High Throughput Testing And Biomarker Development | Leadership |
Chris Eberlein | Director Of Product & Method Development | Leadership |
Daniela Osterholz | Global Head Of HR | Leadership |
Till Wegner | Director Procurement, Warehouse & Logistics | Leadership |
Vipin Singh | Head Of Operations | Leadership |
Jorge Pinto Basto | Vice President Medical Genetics | Leadership |
Jens Kriwolat | Vice President - IT Business Relationship Management & Project Management Office | Leadership |
Reto H. Wenger | Vice President ICS (sox) & SEC Compliance Officer | Director Centogene Switzerland AG | Leadership |
Giovanni Zifarelli | Senior Director Business Development | Leadership |
Lennart Streibel | VP Corporate Development, Investor Relations, And Communications | Leadership |
Martin Shumanov | Head Of Sales Northern Europe | Leadership |
Aida Bertoli Avella | Director Of Medical Genetics & Genomic Research | Leadership |
Dr. Marc Steder | Vice Director Pharma Project Management | Leadership |
Antje Ladwig | Head Of Customer Support | Leadership |
Canan Has | Head Of Data Insights | Leadership |
36 more people are available in the full profile.
Complete people profiles for Centogene
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Centogene
Centogene is a publicly listed company on the OTC with ticker symbol CNTGF in USA, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date07 Nov 2019
- Listed onOTCMKTS: CNTGF
- Listed entityCentogene N.V.
- Exchange sectorCommercial services
- ISINNL0014040206
- Share price$0.12 (+0.92% on the day) · 2026-05-11
- Market capitalisation$3.6M
- Volume (last session)5,000
- Analyst consensusNo rating
Financials of Centogene
Figures of Centogene India Private Limited, the primary company behind Centogene, for FY 2025. Revenue was ₹3.64 Cr (+4% year on year). Net loss was -₹45.4 Lakh (-12% margin). EBITDA was -₹45.3 Lakh (-12% margin). Revenue has grown at a compounded annual rate of +5% over three years and -5% over five years.
- ₹3.64 CrRevenue · FY 2025 · +4% YoY
- -₹45.4 LakhNet loss · -12% margin
- -₹45.3 LakhEBITDA · -12% margin
- ₹2 LakhPaid-up capital
- 11Employees (provident fund records)
- +5%Revenue CAGR, 3 years
- -5%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2023 | $52.5M | -$38.4M | -$34.1M |
| 2022 | $49.9M | -$33.5M | -$30.4M |
| 2021 | $49.9M | -$54.8M | -$46.6M |
| 2020 | $146.3M | -$24.4M | -$7.7M |
Balance sheet, profit and loss, cash flow and ratios of Centogene India Private Limited are on its company page.
Detailed financial statements for Centogene
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Centogene
4 dated milestones of Centogene across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Centogene is founded.
- Funding First funding round of $28.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $16.8M.
Competitors of Centogene
Centogene has 9 listed competitors in our database, 8 of them funded. They include Invitae, Strand Life Sciences, Myriad Genetics, Genome Medical and Fulgent Genetics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| invitae.com | 2010 | San Francisco, United States | $189.56M | 1,700 | Home-based genetic tests for detecting diseases are provided to individuals. | |
| strandls.com | 2000 | Bengaluru, India | $34.88M | 532 | Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery | |
| myriad.com | 1991 | United States | – | 2,700 | Molecular diagnostics and personalized medicine for cancer are developed. | |
| genomemedical.com | 2016 | Monterey, United States | $172.98M | 84 | Genomic testing services are provided clinically and directly to consumers. | |
| fulgentgenetics.com | 2011 | Temple, United States | $64.25M | 591 | Provider of genetic testing services for carrier screening cardiovascular diseases, epilepsy and cancer | |
| anchordx.com | 2015 | Guangzhou, China | $73M | – | High-throughput gene sequencing platform is developed for clinical diagnostics. | |
| blueprintgenetics.com | 2012 | Espoo, Finland | $19.86M | – | Genetic diagnostics and clinical interpretation for hereditary diseases are provided. | |
| celmatix.com | 2009 | New York, United States | $24.89M | 27 | Fertility decisions are optimized using data analytics and genomics. | |
| asaren.ai | 2020 | Jakarta, Indonesia | $8.15M | – | AI-powered platform for precision medicine and longevity research is developed. |
Detailed competitors of Centogene
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Centogene
The website of Centogene (centogene.com) receives about 28.5K visits a month.
- Monthly visits28.5K
▲ 25.8% vs previous month
Websites whose visitors overlap most with Centogene. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| anova-irm.com | 100% | – | #1,372,832 | View details | |
| anna-ctrus.de | 98% | – | #12,654,456 | View details | |
ltd.aruplab.com | ltd.aruplab.com | 94% | – | – | – |
| progeriaresearch.org | 94% | 14.1K | #1,934,048 | View details | |
| preventiongenetics.com | 93% | 24.4K | #1,074,192 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 22 similar websites and full traffic analytics for Centogene
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 22 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Centogene (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Centogene
Complete news archive for Centogene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Centogene
Centogene was founded in 2006 and raised its 1st funding round 11 years after it was founded.
Centogene is headquartered in Rostock, Germany. It is registered at Rostock, Mecklenburg-vorpommern, Germany.
Centogene is a funded company, having raised a total of $28.02M across 3 funding rounds to date. The company's 1st funding round was a Series A of $28.02M, raised on Jun 2017.
Centogene has 11 employees.
The primary company behind Centogene, Centogene India Private Limited, reported revenue of ₹3.64 Cr for FY 2025, up 4% year on year.
Founded in 2006 in Rostock, Germany, operations focus on the genetic diagnostics sector. A database called CentoMD is maintained, containing disease-causing mutations with a phenotype-genotype search tool based on the Human Phenotype Ontology. Genetic panel tests and single mutation tests are offered, alongside analytical services for neonatal screening of congenital diseases, as well as detection of breast cancer, mitochondrial disorders, infertility, stroke, vascular dementia, somatic cancer mutations, and Fabrys disease.
Centogene's top competitors include Strand Life Sciences, Fulgent Genetics and Myriad Genetics.
Centogene offers CentoGenome, CentoXome, MOx, and NGS Panels.
Yes, Centogene is publicly traded on OTC under the ticker symbol CNTGF.
Centogene has 4 investors. Key investors include Deutsche Private Equity, Careventures, TVM Capital Life Science, and Crédit Mutuel Equity.
Centogene operates through Centogene India Private Limited.
The legal entities of Centogene currently have 3 directors, including Nabendu Das, Francisco De Borja Valor Martinez, Dawood Babu Dudekula.